Federal contract award
75F40123C00213
ROLE OF EXCIPIENTS AND EXCIPIENT SUBSTITUTION IN TOPICAL SEMI-SOLID FORMULATIONS AND THEIR EFFECT ON PRODUCT PERFORMANCE AND QUALITY
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $324.5K |
| Current contract value | $324.5K |
| Potential contract value / ceiling | $964.8K |
| Start date | Sep 29, 2023 |
| Current end date | Dec 29, 2025 |
| Potential end date | Sep 29, 2027 |
| Latest award activity | Jan 7, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 7, 2026 | P00004 | $0 | NO COST MODIFICATION TO CHANGE THE SCOPE OF THE DELIVERABLE PLAN. |
| Sep 26, 2025 | P00003 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 29, 2025. |
| Nov 6, 2024 | P00002 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 29, 2025. |
| May 9, 2024 | P00001 | $0 | THE PURPOSE OF THIS ZERO-DOLLAR MODIFICATION IS TO CHANGE THE PAYMENT PLAN. |
| Sep 29, 2023 | 0 | $324.5K | ROLE OF EXCIPIENTS AND EXCIPIENT SUBSTITUTION IN TOPICAL SEMI-SOLID FORMULATIONS AND THEIR EFFECT ON PRODUCT PERFORMANCE AND QUALITY |
Estimated positioning window
Oct 25, 2026 – Mar 29, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-29 (339 days from calculation)
- +35 points
- 15 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2026-01-07
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | May 18, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | May 18, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 17, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 17, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 3, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 3, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 17, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 17, 2022 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 14, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 14, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.